Skinvisible, Inc. (SKVI): Total Assets
$127.6K
As of 2025-12-31
$123.3K
As of 2026-06-30
-19.7%
3-year compound annual growth
-8.6%
5-year compound annual growth
-10.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $127.6K | -19.4% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $158.2K | -2.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $162.9K | -34.0% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $246.8K | +8.6% | 2024-04-16, Balance as of period end |
| 2021-12-31 | $227.3K | +13.5% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $200.2K | +10.2% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $181.8K | -17.5% | 2021-04-15, Balance as of period end |
| 2018-12-31 | $220.4K | -65.1% | 2020-05-14, Balance as of period end |
| 2017-12-31 | $632.2K | +86.2% | 2019-04-15, Balance as of period end |
| 2016-12-31 | $339.6K | -15.2% | 2018-03-23, Balance as of period end |
| 2015-12-31 | $400.5K | -38.0% | 2017-04-17, Balance as of period end |
| 2014-12-31 | $646.1K | -26.1% | 2016-04-14, Balance as of period end |
| 2013-12-31 | $874.1K | +15.9% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $754.2K | +154.0% | 2014-04-11, Balance as of period end |
| 2011-12-31 | $296.9K | +8.8% | 2013-04-16, Balance as of period end |
| 2010-12-31 | $273.0K | n/a | 2012-11-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $127.6K | -19.4% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $5.56M | -10.3% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $225.9K | -13.7% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $12.00M | +165.1% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $29.72M | +63.0% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $17.41M | -14.2% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $340.05M | -30.7% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $2.82M | -17.4% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $279.93M | +100.9% |
Compare SKVI, JUNS, BDPT, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗